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Intra-bone marrow (IBM) stem cell transplant (SCT) technique
has been recently developed and several clinical and experimental
studies reported that IBM-SCT is associated with high rate of en-
graftment and low incidence of acute GVHD. Idiopathic pneumonia
syndrome (IPS) is a significant cause ofmortality and remains amajor
obstacle after allogeneic SCT. In the present study, the extent of IPS
after IBM-SCT was compared with that after conventional intrave-
nous SCT (IV- SCT) by using a lethally irradiated B6(H-2b) into F1
(H-2b/d) mouse IPS model. IBM-SCT showed significantly im-
proved the clinical GVHD score and reduced total cells and
CD3+Tcells in bronchoalveolar lavage fluid compared with IV-
SCT (p \ 0.05). Histopathological examination of the lung at 6
weeks post SCT showed significantly reduced IPS pathology in re-
cipients of IBM-SCT(p\0.05). Recipient mice were imaged at dif-
ferent times, ranging from 1 hour to 3 days using a lethally irradiated
luciferase expressing transgenic FVB/N (H-2q) into BALB/c (H-2d)
mouse model. The majority of injected donor cells were trapped in
the lung one hour after IV- SCT. In contrast, significant fewer cells
were localized in the lung after IBM-SCT (2.07 vs. 6.30 x 106 pho-
tons/sec/animal, p\ 0.01). Although donor cells decreased in the
lung 2 to 3 hours after SCT, continued increase in donor cells
occurred in the lung from 6 hours to 3days after both IV and
IBM- SCT. Significantly more donor cells detected in the lung
from 6 hours to 3days after IV- SCT compared with that after
IBM-SCT (p\0.001). Taken together, IBM-SCT reduces trapping
of injected donor cells in the lung and ameliorates IPS after alloge-
neic SCT. Targeting donor cells trafficking in the lung may be
a promising strategy for preventing IPS.472
PLASMA CYTOKINE CONCENTRATIONS ACCORDING TO CHRONIC GVHD
SUBTYPE
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Finding biomarkers for the phenotype and activity of chronic
GVHD (cGVHD) may improve understanding of the disease and
allow tailored therapy. We examined plasma levels of cytokines in
hematopoietic cell transplant (HCT) recipients, comparing levels
of patients with and without cGVHD, and among 3 clinical cGVHD
subgroups.
Methods: Using 867 assessments for 336 individual cGVHD pa-
tients from 6 centers in the Chronic GVHD Consortium, k-means
hierarchical clustering identified three clinical subtypes of cGVHD
based on the Lee symptom scale, a self-report cGVHD measure
with 7 subscales. Plasma samples were selected from a single center
(Fred Hutchinson Cancer Research Center) as archetypes for the 3
cGVHD subtypes: 1) high symptoms (‘High’, n5 20), 2) high symp-
toms but without oral or GImanifestations (‘High, not mouth/GI’, n
5 20), 3) low symptoms (‘Low’, n 5 20). Samples obtained from
HCT recipients without cGVHD served as controls (n5 10). Six ad-
ditional cGVHD samples that were not easily classified into a clinical
phenotype were included in the cGVHD vs. no cGVHD analysis
only. Plasma levels of IL-4, IL-5, IL-6, IL-8, IL-10, IL-17A,
IL-17F, IFN-gamma, MCP-1, TNFR-II, and TGFb1, 2, 3 were
measured using standardized Luminex assays. TGFb3 results wereexcluded for technical reasons. Plasma BAFF levels were measured
by ELISA. Linear regression models compared log-transformed
cytokine levels for cGVHD versus control, and between cGVHD
subtypes, controlling for plate effects.
Results: Median TNFR-II levels were estimated at 54% higher in
cGVHD patients compared to controls (ratio1.54, 95% CI 1.13-
2.09, p5 0.007) but did not differ among cGVHD subtypes. Several
other cytokines (TGFb1, TGFb2, IL-17F and IL-17A) had 0.01\p
\ 0.05 in specific comparisons but should be interpreted cautiously
because of multiple testing. Other cytokines were not found to differ
between cGVHD and controls or among 3 cGVHD subtypes.
Conclusions: TNFR-II was higher in cGVHD than patients
without cGVHD. These preliminary results did not confirm other
putative cGVHD biomarkers reported by others.
High vs. High, High, not High vs. cGVHD vs.
not mouth/GI mouth/ GI vs. Low Low ControlCytokine n
ratio*
(p-value)
ratio*
(p-value)
ratio*
(p-value)
ratio*
(p-value)IL_4 76 0.84 (—) 1.14 (—) 0.96 (—) 1.01 (—)
IL_5 76 0.81 (—) 1.06 (—) 0.86 (—) 1.03 (—)
IL_6** 47 0.82 (—) 0.83 (—) 0.68 (—) 1.01 (—)
IL_8 76 0.91 (—) 0.90 (—) 0.82 (—) 1.28 (—)
IL_10 76 0.90 (—) 0.99 (—) 0.89 (—) 1.30 (—)
IL_17A 76 0.81 (—) 1.12 (—) 0.92 (—) 1.56 (0.04)
IL_17F 76 0.92 (—) 0.90 (—) 0.83 (0.04) 1.05 (—)
IFNg 76 0.88 (—) 0.98 (—) 0.86 (—) 1.07 (—)MCP_1 76 0.89 (—) 1.02 (—) 0.90 (—) 1.19 (—)
sTNFR_II 76 1.15 (—) 1.03 (—) 1.18 (—) 1.54 (0.007)
TGFb1 76 0.62 (0.10) 2.00 (0.02) 1.23 (—) 1.08 (—)
TGFb2 75 0.56 (0.08) 2.21 (0.02) 1.25 (—) 1.35 (—)
BAFF 76 1.11 (—) 0.86 (—) 0.96 (—) 1.12 (—)*Ratio of median estimated concentration for first group over median
for second group. (Group comparisons are ratios due to the log trans-
formation of cytokine concentrations in regression models.)
**Concentrations on one plate were below the assay limit of detection.
– p > 0.10.473
ADOPTIVELY TRANSFERRED NK CELLS HOME TO TUMOR SITES AND
ACCUMULATE WITH TUMOR GROWTH BUT DO NOT LEAD TO TUMOR
REGRESSION IN A MURINE B-CELL LYMPHOMA MODEL
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Introduction: Natural killer (NK) cells can reject tumor in in vitro
cytotoxicity experiments and in murine models where depletion of
endogenous NK cells leads to accelerated tumor growth. Given
that allogeneic NK cells can be safely transferred into mice and
humans, it is now important to investigate whether these NK cells
can home to tumor.
Methods: A20 B-cell lymphoma cells (1 x 10^6) were injected
subcutaneously into BalbC recipients at the same time as total
body irradiation and a T-cell depleted bone marrow transplant
from MHC-mismatched wild-type FVB donors. Once the tumor
became palpable (10-14 days), mice were injected intravenously
with 0.5 x 10^6 fresh NK cells derived from luciferase-trans-
genic (Luc+) FVB donors. Some animals received intraperito-
neal rhIL-2. Tumor growth was monitored by regular caliper
measurements and NK cell trafficking was evaluated by biolumi-
nescent imaging (BLI). Animals were sacrificed when the tumor
began to ulcerate, and the tumor mass as well as control tissues
were harvested for immune cell phenotyping and functional
studies.
Results:NK cells infused into control non-tumor bearing animals
homed to lymph nodes, spleen and liver with a maximal BLI signal
at the end of the second week as previously shown (Olson et al,
J Immunol 2009) By contrast, in tumor bearing-animals the Luc+
NK cells homed to lymphoid organs in the first week, followedS323
